Unigene Laboratories, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Unigene Laboratories, Inc. - Product Pipeline Review - 2012” provides data on the Unigene Laboratories, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Unigene Laboratories, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Unigene Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Unigene Laboratories, Inc.; Unigene Laboratories, Inc. - Key Therapeutics; Unigene Laboratories, Inc. - Pipeline Overview and Promising Molecules; Unigene Laboratories, Inc. - News; Unigene Laboratories, Inc. - Latest Updates; Unigene Laboratories, Inc. - Pipeline; Unigene Laboratories, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Unigene Laboratories, Inc. - Product Pipeline Review - 2012” provides data on the Unigene Laboratories, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Unigene Laboratories, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Unigene Laboratories, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Unigene Laboratories, Inc. - Brief Unigene Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Unigene Laboratories, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Unigene Laboratories, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Unigene Laboratories, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Unigene Laboratories, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Unigene Laboratories, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Unigene Laboratories, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Unigene Laboratories, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Unigene Laboratories, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Unigene Laboratories, Inc.; Unigene Laboratories, Inc. - Key Therapeutics; Unigene Laboratories, Inc. - Pipeline Overview and Promising Molecules; Unigene Laboratories, Inc. - News; Unigene Laboratories, Inc. - Latest Updates; Unigene Laboratories, Inc. - Pipeline; Unigene Laboratories, Inc. - Discontinued/Dormant Projects
Unigene Laboratories, Inc. Snapshot
Unigene Laboratories, Inc. Overview
Key Information
Key Facts
Unigene Laboratories, Inc. – Research and Development Overview
Key Therapeutic Areas
Unigene Laboratories, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Unigene Laboratories, Inc. – Pipeline Products Glance
Unigene Laboratories, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Unigene Laboratories, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Unigene Laboratories, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Unigene Laboratories, Inc. – Drug Profiles
Annexin Analogs
Product Description
Mechanism of Action
R&D Progress
Anti-Inflammatory Peptides
Product Description
Mechanism of Action
R&D Progress
OSTORA
Product Description
Mechanism of Action
R&D Progress
PTH Analogs
Product Description
Mechanism of Action
R&D Progress
UGP281
Product Description
Mechanism of Action
R&D Progress
Unigene Laboratories, Inc. – Pipeline Analysis
Unigene Laboratories, Inc. – Pipeline Products by Therapeutic Class
Unigene Laboratories, Inc. – Pipeline Products By Target
Unigene Laboratories, Inc. – Pipeline Products by Route of Administration
Unigene Laboratories, Inc. – Pipeline Products By Mechanism of Action
Unigene Laboratories, Inc. – Recent Pipeline Updates
Unigene Laboratories, Inc. - Dormant Projects
Unigene Laboratories, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Unigene Laboratories, Inc., Recent Developments
Unigene Laboratories, Inc.- Press Release
Jun 28, 2012: Unigene Announces Presention Of Oral PTH Phase II Proof-Of-Concept Data At Upcoming Scientific Conferences
May 22, 2012: Unigene Reports Positive Data From Preclinical Studies Of UGP281
Mar 21, 2012: Tarsa Therapeutics Signs Commercial Supply Agreement For Ostora Oral Calcitonin Product With QS Pharma
Jan 11, 2012: Unigene Laboratories Receives US Patent For Peptide-Based Technology For Treatment Of Obesity
Dec 17, 2009: Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program
Dec 10, 2009: Unigene Laboratories Announces Data Monitoring Committee (DMC) Recommends To Continue Phase III Study Of Calcitonin For Osteoporosis And Osteoarthritis
Mar 16, 2009: Unigene Reports Positive PTH Clinical Study Results
Financial Deals Landscape
Unigene Laboratories, Inc., Deals Summary
Unigene Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Tarsa Therapeutics Secures $9 Million In Final Tranche Of Venture Financing Round
Partnerships
Unigene Labs Enters Into Joint Venture Agreement With Nordic Bioscience
Unigene Labs Enters Into Co-Development Agreement With GlaxoSmithKline
Unigene Forms Joint Venture With SPG
Licensing Agreements
Unigene Amends Licensing Agreement With GlaxoSmithKline
Unigene Labs Enters Into Licensing Agreement With Tarsa Therapeutics
Unigene Labs Enters Into Licensing Agreement With Queen Mary, University of London
Unigene Labs Enters Into Licensing Agreement With Novartis
Equity Offering
Unigene Labs Completes Private Placement Of Common Stock For $1.5 Million
Unigene Labs Completes Private Placement Of $13 Million
Debt Offering
Unigene Labs Completes Private Placement Of Secured Non-Convertible Senior Notes For $5 Million
Unigene Labs Completes Private Placement Of Notes For $15 Million
Asset Transactions
Unigene Labs Divests Non-Core Assets To Kieran Murphy
Acquisition
China Pharma To Acquire 45% Stake In Unigene Biotech From Unigene Labs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Unigene Laboratories, Inc., Key Information
Unigene Laboratories, Inc., Key Facts
Unigene Laboratories, Inc. – Pipeline by Indication, 2012
Unigene Laboratories, Inc. – Pipeline by Stage of Development, 2012
Unigene Laboratories, Inc. – Monotherapy Products in Pipeline, 2012
Unigene Laboratories, Inc. – Phase III, 2012
Unigene Laboratories, Inc. – Phase II, 2012
Unigene Laboratories, Inc. – Pre-Clinical, 2012
Unigene Laboratories, Inc. – Pipeline By Therapeutic Class, 2012
Unigene Laboratories, Inc. - Pipeline By Target, 2012
Unigene Laboratories, Inc. – Pipeline By Route of Administration, 2012
Unigene Laboratories, Inc. – Pipeline Products By Mechanism of Action, 2012
Unigene Laboratories, Inc. – Recent Pipeline Updates, 2012
Unigene Laboratories, Inc. - Dormant Developmental Projects,2012
Unigene Laboratories, Inc., Other Locations
Unigene Laboratories, Inc., Deals Summary
Tarsa Therapeutics Secures $9 Million In Final Tranche Of Venture Financing Round
Unigene Labs Enters Into Joint Venture Agreement With Nordic Bioscience
Unigene Labs Enters Into Co-Development Agreement With GlaxoSmithKline
Unigene Forms Joint Venture With SPG
Unigene Amends Licensing Agreement With GlaxoSmithKline
Unigene Labs Enters Into Licensing Agreement With Tarsa Therapeutics
Unigene Labs Enters Into Licensing Agreement With Queen Mary, University of London
Unigene Labs Enters Into Licensing Agreement With Novartis
Unigene Labs Completes Private Placement Of Common Stock For $1.5 Million
Unigene Labs Completes Private Placement Of $13 Million
Unigene Labs Completes Private Placement Of Secured Non-Convertible Senior Notes For $5 Million
Unigene Labs Completes Private Placement Of Notes For $15 Million
Unigene Labs Divests Non-Core Assets To Kieran Murphy
China Pharma To Acquire 45% Stake In Unigene Biotech From Unigene Labs
LIST OF FIGURES
Unigene Laboratories, Inc. – Pipeline by Indication, 2012
Unigene Laboratories, Inc. – Pipeline by Stage of Development, 2012
Unigene Laboratories, Inc. – Monotherapy Products in Pipeline, 2012
Unigene Laboratories, Inc. – Pipeline By Therapeutic Class, 2012
Unigene Laboratories, Inc. Overview
Key Information
Key Facts
Unigene Laboratories, Inc. – Research and Development Overview
Key Therapeutic Areas
Unigene Laboratories, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Unigene Laboratories, Inc. – Pipeline Products Glance
Unigene Laboratories, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Unigene Laboratories, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Unigene Laboratories, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Unigene Laboratories, Inc. – Drug Profiles
Annexin Analogs
Product Description
Mechanism of Action
R&D Progress
Anti-Inflammatory Peptides
Product Description
Mechanism of Action
R&D Progress
OSTORA
Product Description
Mechanism of Action
R&D Progress
PTH Analogs
Product Description
Mechanism of Action
R&D Progress
UGP281
Product Description
Mechanism of Action
R&D Progress
Unigene Laboratories, Inc. – Pipeline Analysis
Unigene Laboratories, Inc. – Pipeline Products by Therapeutic Class
Unigene Laboratories, Inc. – Pipeline Products By Target
Unigene Laboratories, Inc. – Pipeline Products by Route of Administration
Unigene Laboratories, Inc. – Pipeline Products By Mechanism of Action
Unigene Laboratories, Inc. – Recent Pipeline Updates
Unigene Laboratories, Inc. - Dormant Projects
Unigene Laboratories, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Unigene Laboratories, Inc., Recent Developments
Unigene Laboratories, Inc.- Press Release
Jun 28, 2012: Unigene Announces Presention Of Oral PTH Phase II Proof-Of-Concept Data At Upcoming Scientific Conferences
May 22, 2012: Unigene Reports Positive Data From Preclinical Studies Of UGP281
Mar 21, 2012: Tarsa Therapeutics Signs Commercial Supply Agreement For Ostora Oral Calcitonin Product With QS Pharma
Jan 11, 2012: Unigene Laboratories Receives US Patent For Peptide-Based Technology For Treatment Of Obesity
Dec 17, 2009: Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program
Dec 10, 2009: Unigene Laboratories Announces Data Monitoring Committee (DMC) Recommends To Continue Phase III Study Of Calcitonin For Osteoporosis And Osteoarthritis
Mar 16, 2009: Unigene Reports Positive PTH Clinical Study Results
Financial Deals Landscape
Unigene Laboratories, Inc., Deals Summary
Unigene Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Tarsa Therapeutics Secures $9 Million In Final Tranche Of Venture Financing Round
Partnerships
Unigene Labs Enters Into Joint Venture Agreement With Nordic Bioscience
Unigene Labs Enters Into Co-Development Agreement With GlaxoSmithKline
Unigene Forms Joint Venture With SPG
Licensing Agreements
Unigene Amends Licensing Agreement With GlaxoSmithKline
Unigene Labs Enters Into Licensing Agreement With Tarsa Therapeutics
Unigene Labs Enters Into Licensing Agreement With Queen Mary, University of London
Unigene Labs Enters Into Licensing Agreement With Novartis
Equity Offering
Unigene Labs Completes Private Placement Of Common Stock For $1.5 Million
Unigene Labs Completes Private Placement Of $13 Million
Debt Offering
Unigene Labs Completes Private Placement Of Secured Non-Convertible Senior Notes For $5 Million
Unigene Labs Completes Private Placement Of Notes For $15 Million
Asset Transactions
Unigene Labs Divests Non-Core Assets To Kieran Murphy
Acquisition
China Pharma To Acquire 45% Stake In Unigene Biotech From Unigene Labs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Unigene Laboratories, Inc., Key Information
Unigene Laboratories, Inc., Key Facts
Unigene Laboratories, Inc. – Pipeline by Indication, 2012
Unigene Laboratories, Inc. – Pipeline by Stage of Development, 2012
Unigene Laboratories, Inc. – Monotherapy Products in Pipeline, 2012
Unigene Laboratories, Inc. – Phase III, 2012
Unigene Laboratories, Inc. – Phase II, 2012
Unigene Laboratories, Inc. – Pre-Clinical, 2012
Unigene Laboratories, Inc. – Pipeline By Therapeutic Class, 2012
Unigene Laboratories, Inc. - Pipeline By Target, 2012
Unigene Laboratories, Inc. – Pipeline By Route of Administration, 2012
Unigene Laboratories, Inc. – Pipeline Products By Mechanism of Action, 2012
Unigene Laboratories, Inc. – Recent Pipeline Updates, 2012
Unigene Laboratories, Inc. - Dormant Developmental Projects,2012
Unigene Laboratories, Inc., Other Locations
Unigene Laboratories, Inc., Deals Summary
Tarsa Therapeutics Secures $9 Million In Final Tranche Of Venture Financing Round
Unigene Labs Enters Into Joint Venture Agreement With Nordic Bioscience
Unigene Labs Enters Into Co-Development Agreement With GlaxoSmithKline
Unigene Forms Joint Venture With SPG
Unigene Amends Licensing Agreement With GlaxoSmithKline
Unigene Labs Enters Into Licensing Agreement With Tarsa Therapeutics
Unigene Labs Enters Into Licensing Agreement With Queen Mary, University of London
Unigene Labs Enters Into Licensing Agreement With Novartis
Unigene Labs Completes Private Placement Of Common Stock For $1.5 Million
Unigene Labs Completes Private Placement Of $13 Million
Unigene Labs Completes Private Placement Of Secured Non-Convertible Senior Notes For $5 Million
Unigene Labs Completes Private Placement Of Notes For $15 Million
Unigene Labs Divests Non-Core Assets To Kieran Murphy
China Pharma To Acquire 45% Stake In Unigene Biotech From Unigene Labs
LIST OF FIGURES
Unigene Laboratories, Inc. – Pipeline by Indication, 2012
Unigene Laboratories, Inc. – Pipeline by Stage of Development, 2012
Unigene Laboratories, Inc. – Monotherapy Products in Pipeline, 2012
Unigene Laboratories, Inc. – Pipeline By Therapeutic Class, 2012
